Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Deborah Collyar: What's In It for Patients?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Oct
03
Today In Oncology
FDA Approves First-Line Pirtobrutinib for CLL-SLL
Lung Cancer AI Model May Predict Pneumonitis Risk From Immunotherapy
FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality
Are Narrower Negative Margins Linked to Higher Risk of DCIS Recurrence
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo